470. Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in Patients with Significant Drug Abuse: Outcomes from Global Phase 3 Studies of Delafloxacin (DLX)

BACKGROUND: Delafloxacin (DLX), an IV/oral anionic fluoroquinolone antibiotic, is approved for the treatment of ABSSSI including those due to MRSA and Gram-negative pathogens including P. aeruginosa. Two global phase 3 ABSSSI trials included patients with substance abuse including IV drugs. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Overcash, J Scott, O’Riordan, William, Quintas, Megan, Lawrence, Laura, Tseng, Carol, Cammarata, Sue
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809311/
http://dx.doi.org/10.1093/ofid/ofz360.543

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809311/
http://dx.doi.org/10.1093/ofid/ofz360.543

Ejemplares similares